Alzheimer’s disease is a neurodegenerative disorder. It is the most common one, accounting for the majority of dementia cases worldwide, and it ranks as the sixth-leading cause of death in the United States. An estimated 7.2 million Americans age 65 and older currently live with Alzheimer’s dementia, a number projected to reach 13.8 million by 2060 without major medical breakthroughs.
But knowing the label “neurodegenerative” only gets you so far. What matters is understanding what that means inside the brain, how the disease actually progresses, and what distinguishes it from other conditions that also destroy neurons.
What “Neurodegenerative” Actually Means
Neurodegenerative diseases are a group of chronic, age-associated illnesses defined by the progressive dysfunction and death of specific populations of neurons. The key word is “progressive.” Unlike a stroke, which damages the brain in a single event, neurodegeneration is a slow, ongoing process. Neurons don’t just malfunction temporarily; they deteriorate and eventually die, and the brain cannot replace them at a meaningful rate.
The underlying cause, across nearly all neurodegenerative diseases, is the misprocessing of proteins. Normal proteins fold into specific shapes to do their jobs. In Alzheimer’s, Parkinson’s, Huntington’s, and other related diseases, certain proteins misfold, accumulate, and become toxic. Which protein goes wrong, and where in the brain it accumulates, determines which disease develops and which symptoms appear. In Alzheimer’s, two proteins are central: amyloid-beta and tau.
How Alzheimer’s Destroys Brain Cells
The damage in Alzheimer’s follows a two-part process that researchers sometimes describe this way: amyloid-beta pulls the trigger, and tau fires the bullet.
Amyloid-beta is a protein fragment that, in healthy brains, gets cleared away. In Alzheimer’s, these fragments clump together outside neurons, forming sticky plaques. These plaques attract immune cells in the brain called microglia and astrocytes, which launch an inflammatory response. That inflammation, intended to be protective, becomes chronic and destructive. The immune cells release compounds that disrupt nerve connections and damage synapses, the junctions where neurons communicate. This synaptic loss correlates directly with memory decline and happens before neurons actually die.
Meanwhile, amyloid-beta triggers changes inside neurons that affect tau, a protein normally responsible for stabilizing the internal scaffolding that neurons use to transport nutrients and signals. When amyloid-beta activates certain enzymes, tau gets overloaded with chemical tags (a process called hyperphosphorylation). This causes tau to detach from the scaffolding and clump together into tangles. Without stable scaffolding, the neuron’s internal transport system breaks down. Nutrients can’t reach where they’re needed. Mitochondria, the cell’s energy producers, fragment and fail, leading to energy depletion and a buildup of toxic byproducts. Eventually, the neuron dies.
The interaction between these two proteins also floods neurons with calcium and generates damaging reactive molecules that overwhelm the cell’s ability to protect itself. This cascade of energy failure, calcium overload, and oxidative damage is what makes Alzheimer’s relentlessly progressive.
Where the Brain Shrinks First
The damage doesn’t happen everywhere at once. Alzheimer’s pathology starts in the entorhinal cortex and hippocampus, two structures deep in the temporal lobe that are critical for forming new memories. This is why short-term memory loss is typically the earliest noticeable symptom. Over time, the disease spreads outward to encompass the entire cortex, affecting language, reasoning, spatial awareness, and eventually basic bodily functions. Brain scans can detect this progressive shrinkage, and whole-brain volume loss becomes measurable as the disease advances.
How It Differs From Other Neurodegenerative Diseases
Several diseases fall under the neurodegenerative umbrella, including Parkinson’s, Huntington’s, and various forms of motor neuron disease. What separates them is which proteins misfold and which neurons are targeted. In Parkinson’s, the culprit is a protein called alpha-synuclein, which accumulates in brain regions that control movement, particularly those producing dopamine. This is why Parkinson’s primarily causes tremors, stiffness, and slowed movement rather than the memory loss that defines early Alzheimer’s.
The boundaries aren’t always clean, though. People with Parkinson’s can develop dementia, and when researchers examine their brains, they often find amyloid plaques and tau tangles alongside the alpha-synuclein deposits. Cognitive decline in Parkinson’s correlates with both types of pathology. Alzheimer’s remains distinct in that amyloid and tau are the primary drivers from the outset, and memory impairment is the hallmark early feature.
Genetic Risk Factors
Genetics play a significant role in who develops Alzheimer’s, though they work differently depending on the type. The most common genetic risk factor is a variant of the APOE gene called e4. Carrying one copy of this variant doubles or triples the risk of developing Alzheimer’s. Carrying two copies increases risk 8 to 12 times. It’s important to note that carrying the variant doesn’t guarantee the disease, and many people without it still develop Alzheimer’s.
A much rarer form of Alzheimer’s is caused by deterministic gene mutations, meaning anyone who inherits one of these mutations is very likely to develop symptoms, typically before age 65. Three genes are involved: APP, PSEN1, and PSEN2. These mutations lead directly to the abnormal protein accumulation that defines the disease. This early-onset form accounts for a small fraction of all cases but has been essential for researchers studying how the disease begins.
From Mild Forgetfulness to Diagnosis
Alzheimer’s is now understood as a biological process that begins long before symptoms appear. The 2024 revised criteria from the Alzheimer’s Association define the disease based on the presence of its biological markers, not symptoms alone. Under these criteria, an abnormal result on a core biomarker test (detecting amyloid or tau pathology) is sufficient to establish a diagnosis, even in someone who feels fine. This reflects a shift toward treating Alzheimer’s the way oncology treats cancer: as a biological condition that can be identified and staged before it becomes advanced.
For many people, the first clinical sign is mild cognitive impairment (MCI), a stage where memory problems are noticeable but don’t yet interfere significantly with daily life. Roughly 18% of people diagnosed with MCI progress to dementia within one year, though this rate varies based on underlying pathology and individual factors. Not everyone with MCI has Alzheimer’s, and not everyone with MCI progresses.
How Alzheimer’s Is Detected Now
One of the most significant recent advances is a blood test that measures a specific form of tau protein called p-tau217. This test identified Alzheimer’s disease with 88% to 92% accuracy in clinical studies, according to NIH-funded research. Measuring p-tau217 alone performed nearly as well as more complex testing panels. This is a meaningful shift from the recent past, when confirming Alzheimer’s required expensive brain imaging or an invasive spinal fluid draw. Blood-based testing is making earlier and more accessible detection a practical reality, which matters because the biological process of neurodegeneration begins years, sometimes decades, before the first symptoms surface.